Appili Therapeutics Stock Market Value
| APLI Stock | CAD 0.02 0.01 33.33% |
| Symbol | Appili |
What if' Analysis
Backtesting a what-if scenario on Appili Therapeutics helps investors see how the stock may have behaved if the position had been entered, held, or resized under different historical assumptions. Current market capitalization is about 3.03 Million, enterprise value is near 14.82 Million, and annual revenue is around 100,443. The point is not to predict the future from one chart, but to understand how sensitive the trade has been to timing and holding assumptions.
| 12/19/2025 |
| 03/19/2026 |
An initial 0.00 allocation to Appili Therapeutics on December 19, 2025 held through today would produce 0.00 in overall gains. That corresponds to a 0.0% return on investment in Appili Therapeutics in total over 90 days. Appili Therapeutics competes with or is related to XORTX Therapeutics, and Aptose Biosciences. Peer context can support comparative analysis. Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for... More
Upside and Downside Indicators for Appili Therapeutics Signals
This section highlights upside and downside signals that contextualize Appili Therapeutics price behavior. They compare current price to recent trend and sentiment readings.
| Downside Deviation | 21.67 | |||
| Information Ratio | 0.0401 | |||
| Maximum Drawdown | 50.0 | |||
| Value At Risk | -20.00 | |||
| Potential Upside | 25.0 |
Volatility and Risk Indicators for Appili Therapeutics Summary
Market risk indicators summarize volatility and return dispersion for Appili Therapeutics. The measures summarize variability without implying direction.| Risk Adjusted Performance | 0.0365 | |||
| Jensen Alpha | 0.492 | |||
| Total Risk Alpha | 1.78 | |||
| Sortino Ratio | 0.0233 | |||
| Treynor Ratio | 0.4957 |
Investors who believe in mean reversion view Appili Therapeutics' price extremes not as permanent states but as temporary dislocations that create opportunities for disciplined, contrarian capital allocation.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0365 | |||
| Market Risk Adjusted Performance | 0.5057 | |||
| Mean Deviation | 6.95 | |||
| Semi Deviation | 8.66 | |||
| Downside Deviation | 21.67 | |||
| Coefficient Of Variation | 2935.71 | |||
| Standard Deviation | 12.6 | |||
| Variance | 158.83 | |||
| Information Ratio | 0.0401 | |||
| Jensen Alpha | 0.492 | |||
| Total Risk Alpha | 1.78 | |||
| Sortino Ratio | 0.0233 | |||
| Treynor Ratio | 0.4957 | |||
| Maximum Drawdown | 50.0 | |||
| Value At Risk | -20.00 | |||
| Potential Upside | 25.0 | |||
| Downside Variance | 469.44 | |||
| Semi Variance | 75.01 | |||
| Expected Short fall | -25.93 | |||
| Skewness | 0.4844 | |||
| Kurtosis | 0.9188 |
Appili Therapeutics Backtested Returns
Appili Therapeutics shows a severely unstable volatility profile relative to the chosen timeframe. It has a Sharpe Ratio of 0.0589, evidencing risk-calibrated returns. We identified thirty technical indicators influencing the company's volatility profile. Please evaluate metrics such as Downside Deviation of 21.67, risk-adjusted performance of 0.0365, and mean deviation of 6.95 to review standard deviation behavior. On a scale of 0 to 100, Appili Therapeutics holds a performance score of 4. The company retains a Market Volatility (i.e., Beta) of 0.85, which alludes to possible diversification benefits within a given portfolio. Returns on Appili Therapeutics tend to trail the broader market in strong rallies but hold up better when sentiment turns negative. Please validate Appili Therapeutics' total risk alpha, sortino ratio, and the relationship between the jensen alpha and treynor ratio, to make a quick decision on whether Appili Therapeutics' current price history will revert.
Auto-correlation | 0.12 |
Insignificant predictability
Appili Therapeutics shows insignificant predictability when comparing price series from 19th of December 2025 to 2nd of February 2026 against from 2nd of February 2026 to 19th of March 2026. A strong serial relationship would imply that Appili Therapeutics's recent trajectory contains information about its near-term direction. With a serial correlation of 0.12, less than 12.0% of Appili Therapeutics's price variation is attributable to patterns in preceding intervals.
| Correlation Coefficient | 0.12 | |
| Spearman Rank Test | -0.53 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Pair Trading with Appili Therapeutics
Using Appili Therapeutics in a pair-trading setup can improve risk control because gains and losses are judged against a second position instead of against the market alone. The advantage is that adverse movement in one leg may be partly offset by the other when correlation and thesis alignment hold.
Moving against Appili Stock
| 0.67 | FNV | Franco Nevada | PairCorr |
| 0.64 | CD | Cantex Mine Development Earnings Call This Week | PairCorr |
| 0.62 | PLZ-UN | Plaza Retail REIT | PairCorr |
| 0.62 | RUP | Rupert Resources Earnings Call Today | PairCorr |
| 0.61 | IDL | Imaging Dynamics | PairCorr |
Sophisticated investors use correlation analysis to build Appili Therapeutics replacement strategies that go beyond simple sector matching. Assets with similar factor exposures to Appili Therapeutics provide the most accurate portfolio substitution during tax-loss harvesting periods.
Statistical correlation between Appili Therapeutics and its peers is an essential input for mean-variance portfolio optimization. Lower correlation of Appili Therapeutics with other holdings allows for a more efficient frontier with superior risk-adjusted returns.
Pair evaluation and Correlation analysis for Appili Therapeutics provide hedging context. This approach is commonly reviewed within sectors and across broader groups.More Resources for Appili Stock Analysis
Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help frame valuation context across profits, cash flow, and enterprise value. They help compare Appili across measures in a consistent way.